Abstract
In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles to their clinical implementation.
Keywords: Cell therapy, disease modeling, induced pluripotent stem cells, reprogramming, tissue regeneration, tissue engineering.
Current Stem Cell Research & Therapy
Title:Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling
Volume: 9 Issue: 2
Author(s): Graham G. Walmsley, Jeong Hyun, Adrian McArdle, Kshemendra Senarath-Yapa, Michael S. Hu, Michael T. Chung, Victor W. Wong, Michael T. Longaker and Derrick C. Wan
Affiliation:
Keywords: Cell therapy, disease modeling, induced pluripotent stem cells, reprogramming, tissue regeneration, tissue engineering.
Abstract: In 2006, Dr. Yamanaka created the induced pluripotent stem cell (iPSC) by reprogramming adult fibroblasts back to an immature, pluripotent state. Effectively bypassing the ethical constraints of human embryonic stem cells, iPSCs have expanded the horizons of regenerative medicine by offering a means to derive autologous patient-matched cells and tissues for clinical transplantation. However, persisting safety concerns must be addressed prior to their widespread clinical application. In this review, we discuss the history of iPSCs, derivation strategies, and current research involving gene therapy and disease modeling. We review the potential of iPSCs for improving a range of cell-based therapies and obstacles to their clinical implementation.
Export Options
About this article
Cite this article as:
Walmsley G. Graham, Hyun Jeong, McArdle Adrian, Senarath-Yapa Kshemendra, Hu S. Michael, Chung T. Michael, Wong W. Victor, Longaker T. Michael and Wan C. Derrick, Induced Pluripotent Stem Cells in Regenerative Medicine and Disease Modeling, Current Stem Cell Research & Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574888X09666131217004137
DOI https://dx.doi.org/10.2174/1574888X09666131217004137 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets
Current Genomics Antimicrobial Peptides in Oral Cancer
Current Pharmaceutical Design Improved Hepatic Differentiation Strategies for Human Induced Pluripotent Stem Cells
Current Molecular Medicine Protein Tyrosine Phosphatase SHP-2 as Drug Target
Mini-Reviews in Organic Chemistry Tetralogy of Fallot and Hypoplastic Left Heart Syndrome – Complex Clinical Phenotypes Meet Complex Genetic Networks
Current Genomics Pandemic Influenza: Preventing the Emergence of Novel Strains and Countermeasures to Ameliorate its Effects
Infectious Disorders - Drug Targets Antimicrobial Peptides Present in Mammalian Skin and Gut are Multifunctional Defence Molecules
Current Pharmaceutical Design Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Current Cancer Drug Targets Small Molecules in Stem Cell Research
Current Pharmaceutical Biotechnology The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
Reviews on Recent Clinical Trials Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Design Potential Selective Inhibitors for Treating Cancer by Targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with Core Hopping Approach
Protein & Peptide Letters Tissue Engineering Techniques in Cardiac Repair and Disease Modelling
Current Pharmaceutical Design Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Protein Tyrosine Signaling and its Potential Therapeutic Implications in Carcinogenesis
Current Pharmaceutical Design Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology Genetics of Cardiomyopathies: Novel Perspectives with Next Generation Sequencing
Current Pharmaceutical Design Induced Pluripotent Stem Cell Technology: A Paradigm Shift in Medical Science for Drug Screening and Disease Modeling
Current Medicinal Chemistry The Future of Induced Pluripotent Stem Cells for Cardiac Therapy and Drug Development
Current Pharmaceutical Design